NCT00197223已完成3 期
A Randomized, Double-blind, Placebo-controlled, Post-marketing Phase III Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 6,213
- 试验地点
- 2
- 主要终点
- Incidence of culture confirmed influenza A and/or B during the surveillance period
研究概览
简要总结
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S. under the accelerated approval process; marketing approval most likely will be granted before the start of this clinical trial. GSK proposes to support U.S. licensure of Fluarix with this confirmatory post-marketing study. The purpose of the study is to evaluate the efficacy of a single dose of Fluarix in preventing influenza in adults during the 2005/2006 Influenza season.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or female age between, and including, 18 and 64 years of age at the time of the vaccination.
- •Written informed consent obtained from the subject.
- •Availability to follow up by phone during the study period.
- •Female subjects must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal. If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for two months after vaccination.
排除标准
- •History of hypersensitivity to a previous dose of influenza vaccine.
- •History of allergy or reactions likely to be exacerbated by any component of the vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate or sodium deoxycholate.
- •Acute disease at the time of enrollment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature < 37.5°C).
- •Pregnancy
- •Chronic disorders of the pulmonary or cardiovascular system, including asthma
- •History of requiring regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus.
结局指标
主要结局
Incidence of culture confirmed influenza A and/or B during the surveillance period
次要结局
- Efficacy: Incidence of ILI, Number of days of fever, days of school/work absenteeism, hospitalization related to influenza illness, Incidence of pneumonia, Incidence of PCR confirmed influenza A and/or B
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Creatine, D-Ribose, B1 Vitamin, and B6 Vitamin in Ischemic Heart DiseaseIschemic Heart DiseaseNCT03411369University of Pavia55
撤回
不适用
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.Contraception BehaviorContraceptive UsageContraceptive Method SwitchingContraceptionNCT03725358World Bank
撤回
2 期
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 InfectionCOVID-19NCT05074394Sorrento Therapeutics, Inc.
已完成
1 期
A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsMetabolism and Nutrition DisorderObesityNCT02696148Novo Nordisk A/S24
已完成
4 期
Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and HyperlipidemiaErectile DysfunctionNCT00663845Bayer395